87 related articles for article (PubMed ID: 19409371)
1. A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth.
Kawa S; Matsushita H; Ohbayashi H; Semba K; Yamamoto T
Biochem Biophys Res Commun; 2009 Jul; 384(3):329-33. PubMed ID: 19409371
[TBL] [Abstract][Full Text] [Related]
2. Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.
Xia W; Gerard CM; Liu L; Baudson NM; Ory TL; Spector NL
Oncogene; 2005 Sep; 24(41):6213-21. PubMed ID: 16091755
[TBL] [Abstract][Full Text] [Related]
3. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
[TBL] [Abstract][Full Text] [Related]
4. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response.
Stagg J; Sharkey J; Pommey S; Young R; Takeda K; Yagita H; Johnstone RW; Smyth MJ
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16254-9. PubMed ID: 18838682
[TBL] [Abstract][Full Text] [Related]
5. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.
Wang S; Chen C; Meng Y; Hu S; Zheng L; Song J; Zhang D; Li B; Guo Y
Cancer Lett; 2012 Dec; 325(2):214-9. PubMed ID: 22789781
[TBL] [Abstract][Full Text] [Related]
6. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
[TBL] [Abstract][Full Text] [Related]
7. A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo.
Guojun W; Wei G; Kedong O; Yi H; Yanfei X; Qingmei C; Yankai Z; Jie W; Hao F; Taiming L; Jingjing L; Rongyue C
Endocr Relat Cancer; 2008 Mar; 15(1):149-59. PubMed ID: 18310283
[TBL] [Abstract][Full Text] [Related]
8. Generation of monoclonal antibody CIBCgp185 against C-erbB-2 oncoprotein and its clinical evaluation.
Meenakshi A; Kumar RS; Kumar NS
Hum Antibodies; 2001; 10(3-4):101-7. PubMed ID: 11847421
[TBL] [Abstract][Full Text] [Related]
9. Control of breast tumor cell growth using a targeted cysteine protease inhibitor.
Xing R; Wu F; Mason RW
Cancer Res; 1998 Mar; 58(5):904-9. PubMed ID: 9500448
[TBL] [Abstract][Full Text] [Related]
10. A novel human monoclonal antibody derived from tumor-infiltrating lymphocytes in lung cancer inhibits cancer cell growth with morphological changes.
Aoki M; Saikawa Y; Hosokawa S; Fukuda K; Kumai K; Kubota T; Yoshida M; Otani Y; Kitajima M
Anticancer Res; 2005; 25(6B):3791-8. PubMed ID: 16309165
[TBL] [Abstract][Full Text] [Related]
11. A new human antitumor immunoreagent specific for ErbB2.
De Lorenzo C; Palmer DB; Piccoli R; Ritter MA; D'Alessio G
Clin Cancer Res; 2002 Jun; 8(6):1710-9. PubMed ID: 12060608
[TBL] [Abstract][Full Text] [Related]
12. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy.
Dou S; Yao YD; Yang XZ; Sun TM; Mao CQ; Song EW; Wang J
J Control Release; 2012 Aug; 161(3):875-83. PubMed ID: 22762887
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.
Yu D; Hung MC
Oncogene; 2000 Dec; 19(53):6115-21. PubMed ID: 11156524
[TBL] [Abstract][Full Text] [Related]
14. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure.
Wang J; Feng J; Shi M; Qian L; Chen L; Yu M; Xu R; Shen B; Guo N
Mol Immunol; 2008 Jan; 45(1):106-16. PubMed ID: 17572496
[TBL] [Abstract][Full Text] [Related]
15. Genetically targeted T cells eradicate established breast cancer in syngeneic mice.
Wang H; Wei H; Zhang R; Hou S; Li B; Qian W; Zhang D; Kou G; Dai J; Guo Y
Clin Cancer Res; 2009 Feb; 15(3):943-50. PubMed ID: 19188165
[TBL] [Abstract][Full Text] [Related]
16. An anti-ErbB2 fully human antibody circumvents trastuzumab resistance.
Lu Q; Wang L; Zhang Y; Yu X; Wang C; Wang H; Yang Y; Chong X; Xia T; Meng Y; Wang Y; Lu C; Zhou L; Li B
Oncotarget; 2016 Oct; 7(41):67129-67141. PubMed ID: 27564098
[TBL] [Abstract][Full Text] [Related]
17. [Preparation of monoclonal antibody against human c-erbB2 and identification of its specificity].
Song SX; Li MY; Hou ZH; Liu FY; Lu ZJ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2005 May; 21(3):319-21. PubMed ID: 15862149
[TBL] [Abstract][Full Text] [Related]
18. Target-based therapies in breast cancer: current status and future perspectives.
Normanno N; Morabito A; De Luca A; Piccirillo MC; Gallo M; Maiello MR; Perrone F
Endocr Relat Cancer; 2009 Sep; 16(3):675-702. PubMed ID: 19525314
[TBL] [Abstract][Full Text] [Related]
19. A novel ErbB2 epitope targeted by human antitumor immunoagents.
Troise F; Monti M; Merlino A; Cozzolino F; Fedele C; Russo Krauss I; Sica F; Pucci P; D'Alessio G; De Lorenzo C
FEBS J; 2011 Apr; 278(7):1156-66. PubMed ID: 21288302
[TBL] [Abstract][Full Text] [Related]
20. A caspase-6 and anti-HER2 antibody chimeric tumor-targeted proapoptotic molecule decreased metastasis of human osteosarcoma.
Wang LF; Zhou Y; Xu YM; Qiu XC; Zhou BG; Wang F; Long H; Chen X; Yang TT; Ma BA; Fan QY; Yang AG
Cancer Invest; 2009 Aug; 27(7):774-80. PubMed ID: 19488908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
